Market Overview

PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes

PDL BioPharma (NASDAQ: PDLI) today announced that the adjusted conversion rate for the:

2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) is 169.525 shares of common stock per $1,000 principal amount or approximately $5.90 per share, effective December 10, 2012; 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes) is 148.3827 shares of common stock per $1,000 principal amount or approximately $6.74 per share, effective December 5, 2012; and 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (Series 2012 Notes) is 169.525 shares of common stock per $1,000 principal amount or approximately $5.90 per share, effective December 5, 2012. The conversion rates for the notes are adjusted in connection with the regular quarterly dividend of $0.15 to be paid on December 14, 2012, to all stockholders who own shares of PDL on December 7, 2012, the record date.

Posted-In: News Financing

 

Most Popular

Related Articles (PDLI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free